These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 458631)

  • 1. Pharmacokinetics of heparin. II. Studies of time dependence in rats.
    Bjornsson TD; Levy G
    J Pharmacol Exp Ther; 1979 Aug; 210(2):243-6. PubMed ID: 458631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of heparin. I. Studies of dose dependence in rats.
    Bjornsson TD; Levy G
    J Pharmacol Exp Ther; 1979 Aug; 210(2):237-42. PubMed ID: 458630
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity].
    Jacobs C; Grebe S; Kietzmann M; Mischke R
    Dtsch Tierarztl Wochenschr; 1999 Nov; 106(11):478-81. PubMed ID: 10609418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of recombinant interleukin 2 in humans.
    Konrad MW; Hemstreet G; Hersh EM; Mansell PW; Mertelsmann R; Kolitz JE; Bradley EC
    Cancer Res; 1990 Apr; 50(7):2009-17. PubMed ID: 2317789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacokinetic parameters of digoxin and SC4453 a digoxin analogue, following a single bolus i.v. dose and following an infusion preceeded by an i.v. loading dose in the guinea-pig.
    Randimbivololona F; Lesne M
    J Pharmacol; 1983; 14(1):9-17. PubMed ID: 6834854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats.
    Ekblom M; Hammarlund-Udenaes M; Paalzow L
    J Pharmacol Exp Ther; 1993 Jul; 266(1):244-52. PubMed ID: 8331561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal model for pharmacokinetic approach to individualized heparin dosage regimen for i.v. infusion by constant rate to achieve and maintain a desired clotting time.
    Ritschel WA; Brady ME
    Arzneimittelforschung; 1979; 29(12):1891-4. PubMed ID: 546429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technetium 99m labelled heparin: pharmacokinetics and tissue distribution in rats after vascular surgery.
    Colas-Linhart N; Berthelot JL; Ducret A; Petiet A; Bok B
    Biomed Pharmacother; 1987; 41(4):189-91. PubMed ID: 3620586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of cyclosporine. I. Single dose and constant rate infusion studies in the rabbit.
    Awni WM; Sawchuk RJ
    Drug Metab Dispos; 1985; 13(2):127-32. PubMed ID: 2859157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
    Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
    J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the duration of infusion on the disposition of lidocaine in dogs.
    LeLorier J; Moisan R; Gagné J; Caillé G
    J Pharmacol Exp Ther; 1977 Dec; 203(3):507-11. PubMed ID: 925956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of vindesine infusion.
    Rahmani R; Kleisbauer JP; Cano JP; Martin M; Barbet J
    Cancer Treat Rep; 1985; 69(7-8):839-44. PubMed ID: 2410121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans.
    Ohnuma T; Norton L; Andrejczuk A; Holland JF
    Cancer Res; 1985 Jan; 45(1):464-9. PubMed ID: 3965152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
    Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
    Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Distribution of heparin and its complex compounds in the tissues of animals maintained on an atherogenic diet following intravenous administration of a thromboplastin-heparin complex].
    Ul'ianov AM; Liapina LA; Bazaz'ian GG; Boneva ZhS
    Vopr Med Khim; 1981; 27(4):458-62. PubMed ID: 7293076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity of recombinant human interleukin-2 in rats following intravenous infusion.
    Matory YL; Chang AE; Lipford EH; Braziel R; Hyatt CL; McDonald HD; Rosenberg SA
    J Biol Response Mod; 1985 Aug; 4(4):377-90. PubMed ID: 3875693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of thymidine administered as large doses to rats and mice.
    Hill DL; Noker PE; Duncan GF; El Dareer SM
    Cancer Treat Rep; 1981; 65(5-6):495-9. PubMed ID: 7237470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion.
    Fraile RJ; Baker LH; Buroker TR; Horwitz J; Vaitkevicius VK
    Cancer Res; 1980 Jul; 40(7):2223-8. PubMed ID: 7388790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.